Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11625)	8/8/2018 3:11:39 PM
From: tuck	1 Recommendation Recommended By scaram(o)uche Respond to of 12215

Yup, pretty muted reaction, perhaps expected given that the briefing docs were pretty positive. There was some risk for this AdCom, but not that much. Will take analyst support to move it much farther. Given the cash cushion, it may not get it: sell side feels no need to curry favor since they won't be asked to help with a raise any time soon. OTOH, this company is about the last man standing in the new drugs for acne space. As I've said about PRTK before, I see limited downside from here, but at best a slow grind up. And that's assuming they execute well. One caveat to their "send patient home earlier on the oral antibiotic" strategy is that some nausea showed up with the oral (at home) version. So even if insurers see the value of that strategy, will the scrips be there? Cheers, Tuck